Viatris is an API and finished-dose manufacturer based in United States. It holds 3 valid CEPs across a filed portfolio of 15 molecules. Its filings concentrate with AIFA (IT), EMA and Health Canada. Its GMP standing is certified by EMA, ZLG (DE) and ANSM (FR), among 13 authorities. Its most recent recorded inspection, by US FDA, closed on 13 June 2025 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Troisdorf, United Arab Emirates | Not on file |
| Cologne, United Arab Emirates | Not on file |
| Merignac, United Arab Emirates | Not on file |
| PAVIA, United Arab Emirates | Not on file |
| Galway, United Arab Emirates | Not on file |
| Aurangabad, United Arab Emirates | Not on file |
6 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Amlodipine | EDQM | 2 |
| Irbesartan | SFDA (Saudi Arabia) | 2 |
| Alprazolam | EDQM | 1 |
| Atomoxetine | SFDA (Saudi Arabia) | 1 |
| Bosentan | SFDA (Saudi Arabia) | 1 |
| Candesartan Cilexetil | SFDA (Saudi Arabia) | 1 |
| Celecoxib | SFDA (Saudi Arabia) | 1 |
| Ciprofloxacin | SFDA (Saudi Arabia) | 1 |
| Escitalopram | SFDA (Saudi Arabia) | 1 |
| Lenalidomide | SFDA (Saudi Arabia) | 1 |
| Levofloxacin | SFDA (Saudi Arabia) | 1 |
| Monelukast | SFDA (Saudi Arabia) | 1 |
| Risperidone | SFDA (Saudi Arabia) | 1 |
| Telmisartan | SFDA (Saudi Arabia) | 1 |
| Valsartan | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| AIFA (IT) | 2,101 | None |
| EMA | 2,080 | 62 |
| Health Canada | 1,425 | None |
| FAMHP (BE) | 1,339 | None |
| ANSM (FR) | 1,093 | 23 |
| INFARMED (PT) | 1,092 | None |
| ZLG (DE) | None | 46 |
| ANVISA (Brazil) | None | 13 |
| MHRA (UK) | None | 12 |
| EAEU_EEC | None | 8 |
| NAFDAC (NG) | None | 8 |
| MFDS (Korea) | None | 8 |
| FDA (GH) | None | 7 |
| US FDA | None | 6 |
| SAHPRA (ZA) | None | 3 |
| HSA (SG) | None | 3 |
| TMDA (TZ) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2024 | $116.5M | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Viatris comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.